150 related articles for article (PubMed ID: 16681772)
1. p53, epidermal growth factor, and platelet-derived growth factor in uterine leiomyosarcoma and leiomyomas.
Anderson SE; Nonaka D; Chuai S; Olshen AB; Chi D; Sabbatini P; Soslow RA
Int J Gynecol Cancer; 2006; 16(2):849-53. PubMed ID: 16681772
[TBL] [Abstract][Full Text] [Related]
2. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma.
Leitao MM; Soslow RA; Nonaka D; Olshen AB; Aghajanian C; Sabbatini P; Dupont J; Hensley M; Sonoda Y; Barakat RR; Anderson S
Cancer; 2004 Sep; 101(6):1455-62. PubMed ID: 15316901
[TBL] [Abstract][Full Text] [Related]
3. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential.
O'Neill CJ; McBride HA; Connolly LE; McCluggage WG
Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074
[TBL] [Abstract][Full Text] [Related]
4. Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution's experience.
Lusby K; Savannah KB; Demicco EG; Zhang Y; Ghadimi MP; Young ED; Colombo C; Lam R; Dogan TE; Hornick JL; Lazar AJ; Hunt KK; Anderson ML; Creighton CJ; Lev D; Pollock RE
Ann Surg Oncol; 2013 Jul; 20(7):2364-72. PubMed ID: 23334251
[TBL] [Abstract][Full Text] [Related]
5. Apoptotic and cell cycle regulatory markers in uterine leiomyosarcoma.
Leiser AL; Anderson SE; Nonaka D; Chuai S; Olshen AB; Chi DS; Soslow RA
Gynecol Oncol; 2006 Apr; 101(1):86-91. PubMed ID: 16289259
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes and prognostic markers in uterine leiomyosarcoma: a population-based cohort.
Garcia C; Kubat JS; Fulton RS; Anthony AT; Combs M; Powell CB; Littell RD
Int J Gynecol Cancer; 2015 May; 25(4):622-8. PubMed ID: 25675041
[TBL] [Abstract][Full Text] [Related]
7. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors.
Mittal K; Demopoulos RI
Hum Pathol; 2001 Sep; 32(9):984-7. PubMed ID: 11567229
[TBL] [Abstract][Full Text] [Related]
8. Cell cycle regulatory markers in uterine atypical leiomyoma and leiomyosarcoma: immunohistochemical study of 68 cases with clinical follow-up.
Mills AM; Ly A; Balzer BL; Hendrickson MR; Kempson RL; McKenney JK; Longacre TA
Am J Surg Pathol; 2013 May; 37(5):634-42. PubMed ID: 23552380
[TBL] [Abstract][Full Text] [Related]
9. A role for BRCA1 in uterine leiomyosarcoma.
Xing D; Scangas G; Nitta M; He L; Xu X; Ioffe YJ; Aspuria PJ; Hedvat CY; Anderson ML; Oliva E; Karlan BY; Mohapatra G; Orsulic S
Cancer Res; 2009 Nov; 69(21):8231-5. PubMed ID: 19843854
[TBL] [Abstract][Full Text] [Related]
10. p53 immunoreactivity and mutation of the p53 gene in smooth muscle tumours of the uterine corpus.
Jeffers MD; Farquharson MA; Richmond JA; McNicol AM
J Pathol; 1995 Sep; 177(1):65-70. PubMed ID: 7472782
[TBL] [Abstract][Full Text] [Related]
11. Comparative immunohistochemical and molecular analysis of uterine and extrauterine leiomyosarcomas.
Rao UN; Finkelstein SD; Jones MW
Mod Pathol; 1999 Nov; 12(11):1001-9. PubMed ID: 10574596
[TBL] [Abstract][Full Text] [Related]
12. Loss of ATRX/DAXX expression and alternative lengthening of telomeres in uterine leiomyomas.
Ahvenainen TV; Mäkinen NM; von Nandelstadh P; Vahteristo MEA; Pasanen AM; Bützow RC; Vahteristo PM
Cancer; 2018 Dec; 124(24):4650-4656. PubMed ID: 30423196
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical panel to differentiate endometrial stromal sarcoma, uterine leiomyosarcoma and leiomyoma: something old and something new.
Hwang H; Matsuo K; Duncan K; Pakzamir E; Pham HQ; Correa A; Fedenko A; Mhawech-Fauceglia P
J Clin Pathol; 2015 Sep; 68(9):710-7. PubMed ID: 25991737
[TBL] [Abstract][Full Text] [Related]
14. Expression of Ki-67, P53 and progesterone receptors in uterine smooth muscle tumors. Diagnostic value.
Petrović D; Babić D; Forko JI; Martinac I
Coll Antropol; 2010 Mar; 34(1):93-7. PubMed ID: 20437637
[TBL] [Abstract][Full Text] [Related]
15. Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma.
George S; Barysauskas C; Serrano C; Oduyebo T; Rauh-Hain JA; Del Carmen MG; Demetri GD; Muto MG
Cancer; 2014 Oct; 120(20):3154-8. PubMed ID: 24923260
[TBL] [Abstract][Full Text] [Related]
16. [Expression of bcl-2 and bax protein in uterine leiomyosarcomas and leiomyomas].
Zhang ZL; Zhang Y; Zhou JH
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Apr; 30(2):183-6. PubMed ID: 15898430
[TBL] [Abstract][Full Text] [Related]
17. Expression of thrombospondin 1 (TSP 1) in patients with uterine smooth muscle tumors: an immunohistochemical study.
Bodner-Adler B; Nather A; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
Gynecol Oncol; 2006 Oct; 103(1):186-9. PubMed ID: 16595146
[TBL] [Abstract][Full Text] [Related]
18. The combination of histone deacetylase and p53 expressions and histological subtype has prognostic implication in uterine leiomyosarcoma.
Baek MH; Park JY; Park Y; Kim KR; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
Jpn J Clin Oncol; 2019 Aug; 49(8):719-726. PubMed ID: 31329907
[TBL] [Abstract][Full Text] [Related]
19. Uterine smooth muscle tumors: utility of classification by proliferation, ploidy, and prognostic markers versus traditional histopathology.
Layfield LJ; Liu K; Dodge R; Barsky SH
Arch Pathol Lab Med; 2000 Feb; 124(2):221-7. PubMed ID: 10656730
[TBL] [Abstract][Full Text] [Related]
20. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
